Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9 protein

Journal of Immunotherapy

Volumn 23, Issue 4, 2000, Pages 464-472

  Märten, Angela ^a   Schöttker, Björn ^a   Ziske, Carsten ^a   Weineck, Silvia ^a   Buttgereit, Peter ^a   Huhn, Dieter ^c   Sauerbruch, Tilman ^a   Schmidt Wolf, Ingo G H ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c NONE

Author keywords

CA 19 9; Cytokine induced killer cells; Dendritic cells; Immunotherapy; Lymphocytes

Indexed keywords

CA 19-9 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; COCULTURE; CYTOTOXICITY; CYTOTOXICITY TEST; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE CULTURE; NATURAL KILLER CELL; PRIORITY JOURNAL;

ANTIGENS, DIFFERENTIATION; CA-19-9 ANTIGEN; CARCINOMA; COLONIC NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0342647386     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200007000-00010     Document Type: Article

References (30)

1. Bean P, Mazumder A. Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms. Immunobiology 1992;185:63-77.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 98;392:245-52.
3. Benini L, Cavallini G, Zordan D, et al. A clinical evaluation of monoclonal and polyclonal antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988;3:61-6.
4. Schmidt-Wolf IGH, Lefterova P, Johnston V et al. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 1994;453-58.
5. Schmidt-Wolf IGH, Negrin RS, Kiem HP, Blume KG, Weisman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174:139-49.
6. Schmidt-Wolf IGH, Lefterova P, Metha BA, et al. Phenotypic characterization and identification of effector cells involved in tumor recognition of cytokine-induced killer cells. Exp Hematol 1993;21:1673-9.
7. Grimm EA, Mazunder A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-41.
8. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986;233:1318-21.
9. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153:1687-1696.
10. + killer cells. Blood 1995;86:3493-9.
11. Margolin KA, Negrin RS, Wong KK, et al. Cellular immuno-therapy and autologous transplantation for hematologic malignancy. Immunol Rev 1997;157:231-40.
12. Hwu P, Yannelei J, Kriegler M, et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor alpha cDNA for the gene therapy of cancer in humans. J Immunol 1993;150:4104-15.
13. + NK cell. J Immunol 1992;148:2429-36.
14. Csipai M, Lefterova P, Finke S, et al. Effects of interleukin-7 on proliferation of tumor cells. Cancer Research, Therapy and Control 1996;5:11-16.
15. Zoll B, Lefterova P, Finke S, et al. Generation of cytokine-induced killer (CIK) cells using exogenous interleukin-2 (IL-2), -7 (IL-7) or -12 (IL-12). Cancer Immunol Immunother 1998;47:221-6.
16. Margolin KA, Negrin RS, Wong KK, et al. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 1997;157:231-40.
17. + killer cells. Ann Hematol 1997;74:51-6.
18. Fearnly DB, Mclellen AD, Mannering SI, Hock BD, Hart DNJ. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy. Blood 1997;89:3708-16
19. Alters SE, Gadea JR, Sorich M, et al. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. J Immunother 1998;21:17-26.
20. Hart DNJ. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-87.
21. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-72.
22. Specht JM, Wang G, Do MT, et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997;186: 1213-21.
23. Song W, Kong HL, Carpenter H, et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997;86:1247-56.
24. Schuler G, Steinmann RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997;186:1183-87.
25. Westermann J, Aicher A, Qin Z, et al. Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation. Gene Therapy 1998;5:264-71.
26. Hsu FJ, Benicke C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996;2:52-8.
27. Nestle OF, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 1998;4:328-32.
28. Titzer S, Christiansen O, Manzke O, et al. Vaccination of patients with multiple myeloma using idiotype pulsed autologous dendritic-cells derived from highly purified CD34 progenitor cells. Onkologie 1997;20:263.
29. Choudhurry A, Gajewski JL, Liang JC, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997;89:1133-42.
30. Westermann J, Aicher A, Qin Z, et al. Dendritic cells for autologous tumor vaccination in chronic myeloid leukemia. Cancer Gene Therapy 1997;4:311.